{"id":"W2802931074","doi":"10.1111/bjd.16736","title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":119,"is_retracted":false,"has_abstract":true,"ca_institutions":"Innovaderm (Canada); Guenther Dermatology Research Centre","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Psoriasis; Clinical endpoint; Adverse effect; Internal medicine; Randomized controlled trial; Dermatology; Secukinumab; Pathology; Psoriatic arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002950738,0.001231743,0.003176981,0.0003243387,0.0005105197,0.001135512,0.000867818,0.001781341,0.005687843],"category_scores_gemma":[0.002465232,0.0006789037,0.001495627,0.000302398,0.0009857946,0.000750103,0.0002864903,0.002567873,0.0009663081],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004853598,"about_ca_system_score_gemma":0.001334769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003891204,"about_ca_topic_score_gemma":0.0007325341,"domain_scores_codex":[0.9989875,0.0005604503,0.0000709233,0.000168801,0.0000939057,0.000118352],"domain_scores_gemma":[0.998839,0.0002899269,0.0002884938,0.00008700867,0.00009352096,0.0004021874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9672879,0.009419088,0.0008683231,0.0004543669,0.0008220569,0.00003704958,0.00004614727,0.0002037859,0.004369946,0.00008005893,0.000931712,0.01547959],"study_design_scores_gemma":[0.9554499,0.04190695,0.001733393,0.00001530057,0.0001762389,0.00002349043,0.000007048851,0.0001595322,0.0001592201,0.00005216762,0.0003102286,0.000006628746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9773092,0.007930818,0.001343066,0.001194034,0.0008779213,0.007252493,0.001238699,0.000199617,0.002654242],"genre_scores_gemma":[0.9835426,0.002511862,0.002056347,0.001669585,0.0005177226,0.006911956,0.0008533091,0.00002575441,0.001910902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005687843,"threshold_uncertainty_score":0.01902771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01209403580415269,"score_gpt":0.2528384543173931,"score_spread":0.2407444185132404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}